BTK (C481S)

BTK · Variant type: point · HGVS: p.C481S

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Dasatinib	97.4%	2.6%	87.97
2	Bosutinib	97.1%	2.9%	87.22
3	Pirtobrutinib	96.9%	3.1%	99.49
4	Ibrutinib	96.7%	3.4%	94.74
5	Nintedanib	94.3%	5.7%	90.23
6	Entrectinib	87.1%	12.9%	93.69
7	Repotrectinib	80.2%	19.8%	84.21
8	Pacritinib	79.9%	20.1%	88.64
9	Fostamatinib	78.0%	22.0%	96.74
10	Gilteritinib	76.3%	23.7%	88.97
11	Vandetanib	76.3%	23.7%	95.74
12	Ponatinib	68.9%	31.1%	78.23
13	Brigatinib	67.6%	32.4%	82.96
14	Pemigatinib	66.6%	33.4%	98.23
15	Zanubrutinib	54.6%	45.4%	98.24
16	Canertinib	51.7%	48.3%	96.49
17	Neratinib	44.3%	55.7%	93.18
18	Erdafitinib	42.8%	57.2%	95.71
19	Pralsetinib	35.5%	64.5%	93.43
20	Dacomitinib	32.3%	67.7%	97.99
21	Selpercatinib	32.3%	67.7%	96.72
22	Fedratinib	30.5%	69.5%	96.21
23	Tivozanib	29.1%	70.9%	92.42
24	Sunitinib	27.6%	72.4%	91.73
25	Crizotinib	25.6%	74.4%	91.39

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Dasatinib	97.4%	99.3%	-1.8%
Bosutinib	97.1%	99.3%	-2.2%
Pirtobrutinib	96.9%	97.7%	-0.8%
Ibrutinib	96.7%	98.8%	-2.1%
Nintedanib	94.3%	98.0%	-3.7%
Entrectinib	87.1%	95.1%	-8.0%
Repotrectinib	80.2%	93.7%	-13.5%
Pacritinib	79.9%	80.3%	-0.4%
Fostamatinib	78.0%	81.5%	-3.5%
Gilteritinib	76.3%	87.6%	-11.2%
Vandetanib	76.3%	83.8%	-7.5%
Ponatinib	68.9%	—	—
Brigatinib	67.6%	—	—
Pemigatinib	66.6%	—	—
Zanubrutinib	54.6%	97.4%	-42.8%
Canertinib	51.7%	99.3%	-47.5%
Neratinib	44.3%	93.9%	-49.6%
Erdafitinib	42.8%	—	—
Pralsetinib	35.5%	—	—
Dacomitinib	32.3%	87.2%	-54.9%
Selpercatinib	32.3%	—	—
Fedratinib	30.5%	—	—
Tivozanib	29.1%	—	—
Sunitinib	27.6%	—	—
Crizotinib	25.6%	—	—

Cancer	Organ	Source
lymphoid_neoplasm_haematopoietic_and_lymphoid_tissue	Blood/Lymphatic System	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.7ms